Rexahn Pharmaceuticals Inc. (RNN) Forms Parkinson’s Disease Scientific Advisory Board for Serdaxin Development
Rexahn Pharmaceuticals Inc., a pharmaceutical company focused on commercializing leading oncology therapeutics, CNS disorders and sexual dysfunction, recently formed a Parkinson’s Disease Scientific Advisory Board (SAB) comprised of leading medical researchers in neurology. The SAB will work with Rexahn for the clinical development strategy for the company’s CNS drug candidate Serdaxin. SAB Chairman Dr. William Weiner is the director of the Maryland Parkinson’s Disease and Movement Disorders Center, and professor and chair of the Department of Neurology at the University of Maryland School of Medicine. With more than 40 years of Parkinson’s disease related research behind him, Dr. Weiner recognizes…